Special report: aCGH for the genetic evaluation of patients with developmental delay/mental retardation or autism spectrum disorder.
ثبت نشده
چکیده
©2009 Blue Cross and Blue Shield Association. Reproduction without prior authorization is prohibited. 1 NOTICE OF PURPOSE: TEC Assessments are scientific opinions, provided solely for informational purposes. TEC Assessments should not be construed to suggest that the Blue Cross Blue Shield Association, Kaiser Permanente Medical Care Program or the TEC Program recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service; any particular course of treatment, procedure, or service; or the payment or non-payment of the technology or technologies evaluated. Special Report: aCGH for the Genetic Evaluation of Patients with Developmental Delay/ Mental Retardation or Autism Spectrum Disorder
منابع مشابه
Medical Coverage Policy Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation or Autism Spectrum Disorder - PREAUTH
Description: Chromosomal microarray (CMA) testing has been proposed for detection of genetic imbalances in infants or children with characteristics of developmental delay/intellectual disability or autism spectrum disorder. G-banded karyotyping has for many years been the standard first-line test for this purpose. G-banded karyotyping allows visualization and analysis of chromosomes for chromos...
متن کاملThe role of new genetic technology in investigating autism and developmental delay.
Natasha Shur, MD, Shelly Gunn MD, PhD, Lloyd Feit, MD, Albert K. Oh, MD, Yvette Yatchmink, MD, PhD, and Dianne Abuelo, MD introdUCtion Children with developmental delay and dysmorphic features can present diagnostic and therapeutic challenges. One of the newer genetic technologies, known as chromosomal microarray, or array comparative genomic hybridization (aCGH) has revolutionized our diagno...
متن کاملGenetic Testing for FMR1 Mutations (Including Fragile X Syndrome)
Patient Selection Criteria Coverage eligibility will be considered for fragile X mental retardation 1 (FMR1) mutations the following patient populations: Individuals of either sex with intellectual disability, developmental delay, or autism spectrum disorder (see Policy Guidelines ◊ ). Prenatal testing of fetuses of known carrier mothers (see Policy Guidelines ◊ ). Affected individuals or...
متن کاملThe array CGH and its clinical applications.
Array comparative genomic hybridization (aCGH) is a technique enabling high-resolution, genome-wide screening of segmental genomic copy number variations (CNVs). It is becoming an essential and a routine clinical diagnostic tool and is gradually replacing cytogenetic methods. Most of the clinically available aCGH platforms are designed to detect aneuploidies, well-characterized microdeletion/mi...
متن کاملFibromyalgia in fragile X mental retardation 1 gene premutation carriers.
OBJECTIVE FM is a disorder of altered pain regulation and is characterized by pain, fatigue, poor sleep and psychological impairments; thus, it is classified as a central sensitivity syndrome. Female carriers of a premutation in the fragile X mental retardation 1 (FMR1) gene frequently have widespread musculoskeletal pain and sometimes have been diagnosed with FM, especially if they have the mo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Technology Evaluation Center Assessment Program. Executive summary
دوره 23 10 شماره
صفحات -
تاریخ انتشار 2009